ABAC Therapeutics in collaboration with FNDR and Peptris lead an international project to develop new antibiotics against gram-negative bacteria

ABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and the Foundation for Neglected Disease Research (FNDR), with scientific support from Medicines for Malaria Venture (MMV), leads an international project to optimize a new chemical structure that has shown effectiveness against Gram-negative bacteria, the greatest current threat to public health. In recent decades, there has been a significant increase in the incidence of infections caused by the Gram-negative bacteria known as “the four killers”: Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae.